TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00631592
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01639157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be maintained on oral placebo (0 mg administered 3 times daily) for 6 days each during the study in random order.
Study: NCT00367653
Drug: Azithromycin plus Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azithromycin 1000 mg by mouth (PO) (two 500 mg tablets) once daily (QD) for 3 days(Days 0, 1, 2) plus chloroquine 600 mg base PO once daily for 3 days (Days 0, 1, 2)
Study: NCT00978016
Drug: Placebo-Cohort 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (placebo) for 7 weeks including titration and taper periods
Study: NCT00978016
Drug: PPI
Normalized name: PPIase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD
Study: NCT02958696
Drug: HTL0018318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.
Study: NCT02111096
Drug: LY2409021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02111096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02111096
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02127749
Drug: Endotoxin
Normalized name: Endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups will receive 2 ng/kg LPS (endotoxin) intravenously
Study: NCT05024825
Drug: hydrocodone, acetaminophen and ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the hydrocodone group will receive scheduled doses of hydrocodone, acetaminophen and ibuprofen at scheduled doses. Acetaminophen 15mg/kg (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain.
Study: NCT00006286
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03788343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules are indistinguishable in their appearance from Phe capsules
Study: NCT03168022
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
Study: NCT03168022
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
Study: NCT02187536
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04334317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-071 placebo-matching tablet.
Study: NCT01290003
Drug: Piperacillin-Tazobactam and Amikacin
Normalized name: piperacillin / tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inj Piperacillin-Tazobactam 50 mg/Kg/dose 12 hourly IV X 3 days (6 doses) Inj Amikacin 15 mg/kg/dose 24 hourly IV X 3 days (3 doses)
Study: NCT05485818
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
Study: NCT05485818
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12±4 hours after PCI: 2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
Study: NCT00188045
Drug: Propranolol - Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02969044
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03855982
Drug: Drug inducing myocarditis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs susceptible to induce myocarditis
Study: NCT04650204
Drug: Anticonvulsant Agent
Normalized name: ANTICONVULSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given ASD
Study: NCT01683396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection
Study: NCT04968613
Drug: placebo monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to basic treatment, the patient also received selegiline treatment
Study: NCT00929851
Drug: CHF1535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose
Study: NCT03106428
Drug: MEDI7247
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will enroll patients with R/R AML/MM/DLBCL who will receive MEDI7247 IV
Study: NCT01047254
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03093259
Drug: ABX464
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 is a new Anti-inflammatory drug
Study: NCT03093259
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching with ABX464
Study: NCT04211831
Drug: URO-902
Approvals — FDA: no, EMA: no, PMDA: no
Description: intradetrusor injection
Study: NCT04211831
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intradetrusor injection
Study: NCT00317629
Drug: controlled nitric oxide releasing patch
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily nitric oxide patch application during 20 days
Study: NCT02385474
Drug: 12% SDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% silver diamine fluoride solution, of which the capability of arresting dental caries is not sure
Study: NCT02385474
Drug: 38% SDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 38% silver diamine fluoride solution, of which the capability of arresting dental caries is known
Study: NCT04951869
Drug: Protescal gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protescal gel (0.5 mL) was again applied over the subcutaneous tissue prior to skin closure in Protescal group
Study: NCT03744247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously every 2 weeks
Study: NCT00870844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vials with solution for IV infusion
Study: NCT03732963
Drug: Melatonin (Group M)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
Study: NCT00366795
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration once daily
Study: NCT03906799
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).
Study: NCT00128440
Drug: BEA 2180 BR
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00542633
Drug: VIAject™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage as individually required
Study: NCT00542633
Drug: Regular Human Insulin
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage as individually required
Study: NCT01593397
Drug: Propofol and Fentanyl administration
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol will be administered to all patients via infusion at a dose of 2 mg/kg lean body weight/minute. The infusion will stop once loss of consciousness is reached. Fentanyl will be administered via target controlled infusion to achieve a plasma concentration of 2 ng/ml.
Study: NCT02735902
Drug: Vitamin K antagonist or direct oral anticoagulant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Vitamin K antagonist or direct oral anticoagulant treatment will be administered to obtain an International Normalized Ratio between 2 and 3 as recommended if the treatment is AVK.~The Direct oral anticoagulant treatment : Apixaban 5 mg x2 or 2.5 mg X2, Edoxaban 30 ou 60 mg
Study: NCT01982682
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03164876
Drug: AUT00206
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules of 200mg AUT00206, twice daily, to take orally with food for 4 weeks
Study: NCT03164876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules of placebo, twice daily, to take orally with food for 4 weeks
Study: NCT03860974
Drug: Serratus Plane block (single injection)
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single-injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL of local anesthetic for unilateral surgery; 16 mL of local anesthetic each side for bilateral surgery).
Study: NCT00064987
Drug: gonadotropin releasing hormone (GnRH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
Study: NCT02969382
Drug: Placebo - Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Placebo capsule daily for 4 weeks
Study: NCT00005985
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02088697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02439216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03073876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: prepared placebo looking exactly the same as drug. Participants took placebo by mouth for approximately 6 weeks, and after unblinding, they took donepezil hydrochloride for 6 months.
Study: NCT01050530
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral administration of placebo after breakfast for 7 days
Study: NCT01750190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT00911300
Drug: Vitamin-K-Antagonist
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of different drugs
Study: NCT01366118
Drug: Therapeutic target tailored chemotherapy
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: All pts were treated with Capecitabine (Cap) 625-825 mg/m2/12h M-F.~Ch combination schema was customized based on:~Top- 1 +: Irinotecan (I) 50mg/m2 / in weekly. Top-1 - and ERCC-1 - : Oxaliplatin (O) 50gm/m2/ weekly. Top- 1 - and ERCC-1 + : Neither I nor O. K-Ras or b-Raf mutated (m) : Bevacizumab (B) 5mg/kg every two weeks. K-Ras and B-Raf native (n): Cetuximab (C) 400/250mg/m2 weekly or B (investigator option). Figure 1.~When Cap was in combination with O or I the 625mg/m2 dose was chosen. When Cap was the only chemotherapy agent in combination with B or C the 825mg/m2 dose was chosen
Study: NCT01514461
Drug: LCQ908
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
Study: NCT01514461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
Study: NCT02532686
Drug: DAAOI-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-2000mg/d, oral, for 6 weeks
Study: NCT02532686
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, for 6 weeks
Study: NCT03423797
Drug: 25% AgNO3 solution followed by 5% NaF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF: 11.6mg (F-)/0.5ml (max dose).
Study: NCT03423797
Drug: 25% AgNO3 solution followed by 5% NaF with fTCP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF with fTCP: 11.6mg (F-)/0.5ml (max dose).
Study: NCT03901313
Drug: Treatment B - 400 mg Fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning within 30 minutes (min) after a low-fat standard breakfast meal
Study: NCT03901313
Drug: Treatment C - 200 mg Fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral 200 mg (1 × 200 mg capsule) dose of pexidartinib in the morning within 30 min after a low-fat standard breakfast meal
Study: NCT03864419
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03864419
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03864419
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03864419
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02476019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously
Study: NCT02963779
Drug: LY2775240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02963779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04089449
Drug: PRT811
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT811 will be administered orally
Study: NCT06251440
Drug: Fetal Reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Under ultrasound guidance, intracardiac injection of 0.2 to 3.0 ml of 15% weight/volume (2 miliequivalent/mililiter ) potassium chloride (KCl) was administered via transabdominal route
Study: NCT01349192
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: only subjects greater or equal to 8 years of age, who are not able to tolerate TMP/SMX or whose screening MRSA is resistant to TMP/SMX should be prescribed minocycline.~Adult dose: 100 mg orally twice daily for 14 days Pediatric dose: \< 50 kg : 2mg/kg orally twice daily for 14 days not to exceed 200mg per day.
Study: NCT03919656
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient
Study: NCT03992365
Drug: Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The evening before the colonoscopy: Take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 20 tablets.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 12 tablets.
Study: NCT02608411
Drug: ARQ197
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04139824
Drug: Xanthine Oxidase Inhibitor
Normalized name: Xanthine oxidase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC350189 200mg qd
Study: NCT04139824
Drug: nonsteroidal anti-inflammatory drug
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500mg BID
Study: NCT00199017
Drug: Dexamethasone/Prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00199017
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01223378
Drug: BOL-303259-X
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic solution, various concentrations, once daily (QD) 28 days
Study: NCT01870778
Drug: RLX030
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/mL solution in 6 mL vials
Study: NCT01870778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo solution to serelaxin
Study: NCT00399061
Drug: Systane, Optive, Restasis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systane 30ml (in the eye) instill one drop twice a day in morning and evening Optive 15ml (in the eye) instill one drop twice a day in morning and evening Restasis 0.4ml (in the eye) instill one drop twice a day in morning and evening more frequently if needed
Study: NCT01096472
Drug: LAS41003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT00862043
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo t.i.d.
Study: NCT00470314
Drug: L-Ornithine L-Aspartate
Normalized name: L-ornithine L-aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04257487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic sulodexide 250 LSU
Study: NCT06188221
Drug: Corticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The group without the lidocaine will get an injection with only corticosteroids. The corticosteroid dosage depends on the disease and will be the same as for the group with the lidocaine:
Study: NCT03709706
Drug: Lete-cel
Approvals — FDA: no, EMA: no, PMDA: no
Description: lete-cel will be administered to eligible participants.
Study: NCT00649272
Drug: Ditropan XL® Extended-release tablets, 15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg, single dose fasting
Study: NCT01099566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A pharmacist not otherwise involved in the trial will encapsulate pills consisting of lactose-starch. Six pills will be administered as placebo 2 hours before LPS administration on trial day 1.
Study: NCT02803749
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03234374
Drug: Marcaine 0.25% infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration
Study: NCT01100151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration
Study: NCT03944200
Drug: DA-1229_01(A), Sugamet SR Tab 5/1000mg®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.
Study: NCT03944200
Drug: Sugamet SR Tab 5/1000mg®, DA-1229_01(A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.
Study: NCT00347061
Drug: afuzosin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04241640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02798653
Drug: Choriomon® injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
Study: NCT02798653
Drug: Choriomon® injection+Endometrin ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
Study: NCT02798653
Drug: Endometrin ® vaginal tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
Study: NCT04146103
Drug: Novex
Normalized name: Synovex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally.
Study: NCT01506388
Drug: Vaginal IMN
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMN vaginal 40 mg every 4-6 hours
Study: NCT02961998
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients from experimental group will take celecoxib, except for sorafenib
Study: NCT04174339
Drug: POF
Normalized name: Ta-Poff
Approvals — FDA: no, EMA: no, PMDA: no
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Study: NCT03516656
Drug: Standard heparin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be placed on heparin infusions per their surgeon's discretion.
Study: NCT03516656
Drug: Real time heparin dose adjustment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
Study: NCT01042093
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine 1 mg/ml (0.5 ml)
Study: NCT05850117
Drug: esomeprazole, tripotassium dicitrate bismuthate, tetracycline and levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline combined with levofloxacin quadruple therapy
Study: NCT05850117
Drug: esomeprazole , tripotassium dicitrate bismuthate, tetracycline 500mg and metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard tincture quadruple therapy
Study: NCT00297076
Drug: GW873140
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01790087
Drug: ANX-188 Therapeutic Dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01565889
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily